Skip to main content

Table 9 Sensitivity analysis results for the impact of each parameter on cost-effectiveness

From: Cost-effectiveness analysis of oral anti-viral drugs used for treatment of chronic hepatitis B in Turkey

Parameter

Change

New value

 

Total cost (TL)

YLL

Cost difference (TL)

Year difference

 

Age = 50 years

 

50

TDF

119,604

1.302

   
   

ETV-TDF

161,642

1.347

42,037

0.045

 
   

ETV

162,115

1.347

42,511

0.046

 
   

LdT-TDF

138,182

1.923

18,577

0.622

 
   

3TC-TDF

132,157

2.028

12,552

0.726

 
   

LdT

151,059

2.581

31,455

1.280

 
   

3TC

147,245

4.109

27,640

2.807

 
   

TDF

119,604

2.987

   
   

ETV-TDF

161,642

3.088

42,037

0.101

 
   

ETV

162,115

3.089

42,511

0.102

 

Age = 30 years

 

30

LdT-TDF

138,182

4.429

18,577

1.442

 
   

3TC-TDF

132,157

4.621

12,552

1.634

 
   

LdT

151,059

5.954

31,455

2.967

 
   

3TC

147,245

9.453

27,640

6.465

 
   

TDF

119,411

2.025

   
   

ETV-TDF

161,353

2.079

41,943

0.054

 
   

ETV

161,826

2.079

42,416

0.055

 

HBeAg (−) rate

25 % increase

88 %

LdT-TDF

132,215

2.656

12,804

0.631

 
   

3TC-TDF

127,731

2.907

8320

0.882

 
   

LdT

137,643

3.152

18,233

1.128

 
   

3TC

128,004

5.124

8593

3.099

 
   

TDF

119,798

2.096

   
   

ETV-TDF

161,930

2.183

42,132

0.087

 
   

ETV

162,404

2.183

42,606

0.088

 

HBeAg (−) rate

25 % decrease

53 %

LdT-TDF

144,149

3.445

24,351

1.349

 
   

3TC-TDF

136,582

3.487

16,784

1.391

 
   

LdT

164,475

5.045

44,677

2.949

 
   

3TC

166,486

7.907

46,688

5.811

 
   

TDF

119,573

2.055

   
   

ETV-TDF

161,642

2.131

42,068

0.076

 
   

ETV

162,115

2.131

42,542

0.076

 

TDF: virologic response 48th week in HBeAg (−)

25 % increase

100.0 %

LdT-TDF

138,176

3.049

18,603

0.994

 
   

3TC-TDF

132,148

3.196

12,574

1.140

 
   

LdT

151,059

4.099

31,486

2.043

 
   

3TC

147,245

6.515

27,672

4.460

 
   

TDF

119,711

2.078

   
   

ETV-TDF

161,642

2.131

41,931

0.053

 
   

ETV

162,115

2.131

42,404

0.053

 

TDF: Virologic response 48th week in HBeAg (−)

25 % decrease

69.9 %

LdT-TDF

138,202

3.054

18,491

0.976

 
   

3TC-TDF

132,186

3.202

12,475

1.124

 
   

LdT

151,059

4.099

31,348

2.021

 
   

3TC

147,245

6.515

27,534

4.437

 
   

TDF

119,538

2.049

   
   

ETV-TDF

161,642

2.131

42,103

0.082

 
   

ETV

162,115

2.131

42,577

0.082

 

TDF: Virologic response 48th week in HBeAg (+)

25 % increase

95.2 %

LdT-TDF

138,153

3.044

18,614

0.996

 
   

3TC-TDF

132,118

3.190

12,580

1.141

 
   

LdT

151,059

4.099

31,521

2.050

 
   

3TC

147,245

6.515

27,707

4.467

 
   

TDF

119,671

2.072

   
   

ETV-TDF

161,642

2.131

41,971

0.059

 
   

ETV

162,115

2.131

42,444

0.060

 

TDF: Virologic response 48th week in HBeAg (+)

25 % decrease

57.1 %

LdT-TDF

138,211

3.056

18,540

0.985

 
   

3TC-TDF

132,195

3.204

12,524

1.133

 
   

LdT

151,059

4.099

31,388

2.027

 
   

3TC

147,245

6.515

27,574

4.444

 
   

TDF

140,826

2.060

   
   

ETV-TDF

161,879

2.131

1053

0.070

 
   

ETV

162,115

2.131

1289

0.071

 

TDF annual drug cost

25 % decrease

2796 TL

LdT-TDF

144,943

3.050

4117

0.990

 
   

3TC-TDF

147,174

3.197

6348

1.137

 
   

LdT

151,059

4.099

0233

2.038

 
   

3TC

147,245

6.515

6419

4.455

 
   

TDF

98,383

2.060

   
   

ETV-TDF

161,405

2.131

63,022

0.070

 
   

ETV

162,115

2.131

63,732

0.071

 

TDF annual drug cost

25 % decrease

1677 TL

LdT-TDF

131,421

3.050

33,038

0.990

 
   

3TC-TDF

117,139

3.197

18,756

1.137

 
   

LdT

151,059

4.099

52,676

2.038

 
   

3TC

147,245

6.515

48,862

4.455

 
  1. Tenofovir dominates all comparisons in all scenarios
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us